Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127284871 | 12728487 | 1 | I | 20160318 | 20160905 | 20160909 | 20160909 | EXP | IT-PFIZER INC-2016419886 | PFIZER | 64.00 | YR | M | Y | 0.00000 | 20160909 | MD | IT | IT |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127284871 | 12728487 | 1 | PS | PREGABALIN. | PREGABALIN | 1 | Oral | 75 MG, DAILY | U | 21446 | 75 | MG | |||||||
127284871 | 12728487 | 2 | SS | ENOXAPARIN | ENOXAPARIN | 1 | Subcutaneous | 8 IU, DAILY | 0 | 8 | IU | ||||||||
127284871 | 12728487 | 3 | SS | SORAFENIB | SORAFENIB | 1 | Oral | 800 MG, DAILY | Y | U | 0 | 800 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127284871 | 12728487 | 2 | Vena cava thrombosis |
127284871 | 12728487 | 3 | Hepatocellular carcinoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127284871 | 12728487 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127284871 | 12728487 | Hepatic encephalopathy | |
127284871 | 12728487 | Melaena |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127284871 | 12728487 | 1 | 20160219 | 0 | ||
127284871 | 12728487 | 2 | 20160219 | 0 | ||
127284871 | 12728487 | 3 | 20160306 | 20160318 | 0 |